REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jun. 15, 2016--
Heron Therapeutics, Inc. (NASDAQ: HRTX), a biotechnology company focused
on improving the lives of patients by developing best-in-class medicines
that address major unmet medical needs, announced that Barry D. Quart,
Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at
the JMP Securities Life Sciences ConferenceWednesday, June 22, 2016, at
2:30 p.m. ET (11:30 a.m. PT) in New York, New York.
A live webcast of this presentation and accompanying slides will be
available on the Company’s website at www.herontx.com in
the Investor Resources section. A replay of the presentation will be
archived on the site for 60 days.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a biotechnology company focused on improving
the lives of patients by developing best-in-class medicines that address
major unmet medical needs. Heron is developing novel, patient-focused
solutions that apply its innovative science and technologies to
already-approved pharmacological agents for patients suffering from
cancer or pain. Heron’s goal is to build on therapeutics with well-known
pharmacology by improving their tolerability and efficacy as well as
broadening their potential field of use. For more information, visit www.herontx.com.
This news release contains "forward-looking statements" as defined by
the Private Securities Litigation Reform Act of 1995. Heron cautions
readers that forward-looking statements are based on management’s
expectations and assumptions as of the date of this news release and are
subject to certain risks and uncertainties that could cause actual
results to differ materially. These risks and uncertainties include, but
are not limited to, those associated with: the projected sufficiency of
our capital position for future periods, the review of the SUSTOL NDA by
the FDA, the potential market opportunity for SUSTOL and new products
generally, expected timing and acceptance of the SUSTOL commercial
launch, the progress in the research and development of HTX-019, HTX-011
and our other programs, including the timing of preclinical, clinical,
and manufacturing activities, safety and efficacy results from our
studies, and other risks and uncertainties identified in the Company's
filings with the Securities and Exchange Commission. Forward-looking
statements reflect our analysis only on their stated date, and Heron
takes no obligation to update or revise these statements except as may
be required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160615005330/en/
Source: Heron Therapeutics, Inc.
Investor Relations and Media Contact:
Jennifer Capuzelo, 858-703-6063